


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(Currently amended)** A compound represented by the formula



wherein Ring A represents an optionally substituted pyridine ring which may have one or two C₁₋₄ alkyl groups, X represents an electron-attracting nitrile group, Y represents -CH=CH- or -(CH₂)₂-(CH₂)₂, R¹ represents (1) a C₅₋₇ cycloalkyl group optionally fused with a benzene ring, (2) a C₇₋₁₉ aralkyl group, (3) a 5- or 6-membered heterocyclic ring-C₁₋₄ alkyl group or (4) a C₆₋₁₄ aryloxy-C₁₋₄ alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri-halogeno-C₁₋₄ alkyl group and a C₁₋₄ alkoxy group, and one of R² and R³ each independently represent is a hydrogen atom, an optionally substituted hydrocarbon group selected from the group consisting of a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl and C₇₋₁₉ aralkyl or an optionally substituted heterocyclic group selected from the group consisting of tetrahydropyranyl, pyranyl and pyridyl or a C₁₋₄ alkyl group, and the other is a C₆₋₁₄ aryl group, a C₇₋₁₉ aralkyl group, a C₃₋₁₀ cycloalkyl group, a tetrahydropyranyl group, a pyranyl group or a pyridyl group or a C₁₋₆ alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri- halogeno-C₁₋₄

alkyl group, a C₁₋₄ alkoxy group, a C₁₋₄ alkoxy-carbonyl group, a cyano group, a C₁₋₄ alkyl-carbonylamino group and a hydroxyl group or a salt thereof.

2. **(Cancelled).**

3. **(Cancelled).**

4. **(Cancelled).**

5. **(Cancelled).**

6. **(Cancelled).**

7. **(Original)** (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide,
(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethylphenyl)prop-2-enamide,
(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-methyl-N-phenylprop-2-enamide,
(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3-methylphenyl)prop-2-enamide,
(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(4-hydroxy-3-methoxyphenyl)prop-2-enamide, or salts thereof.

8. (Cancelled).

9. (Currently amended) A ~~medicine~~vanilloid receptor agonist comprising the compound according to claim 1.

10. (Cancelled).

11. (Currently amended) The vanilloid receptor agonist according to claim ~~10-9~~ which is for local administration.

12. (Currently amended) The vanilloid receptor agonist according to claim ~~10-9~~ which is an agent for treating overactive bladder.

13. (Currently amended) The vanilloid receptor agonist according to claim ~~10-9~~ which is an analgesic.

14. (Previously presented) A method of treating overactive bladder, comprising administering to a mammal in need an effective amount of the compound according to claim 1.

15. (Previously presented) An analgesic method comprising administering to a mammal in need an effective amount of the compound according to claim 1.

16. (Canceled).

17. (Canceled).